The myasthenia gravis treatment market is anticipated to grow at a CAGR of 7.14% from US$1.973 billion in 2025 to US$2.785 ...

The US Food and Drug Administration (FDA) has approved a pre-filled syringe version of argenx’s Vyvgart, giving generalised ...

As a result, the muscles become weak when a person performs repeated physical movements. The disease is neither contagious nor inherited but it is often misunderstood as a psychological issue or ...

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile in adult patients with generalized myasthenia gravis, offering a promising ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, ...

WASHINGTON (dpa-AFX) - The U.S. Food and Drug Administration has announced a plan to replace animal testing in the development of monoclonal antibody therapies and other drugs with more effective ...

Shares of argenx SE ARGX rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART ...

The body's immune system mistakenly produces "autoantibodies," or antibodies that attack its own tissues and proteins. In the case of myasthenia gravis, the body produces autoantibodies that target ...

Myasthenia gravis is a rare neuromuscular disorder caused by the production of pathogenic autoantibodies against neuromuscular junction components. About 80-85% of gMG patients have antibodies against ...

Last week­end, re­searchers gath­ered in San Diego for the Amer­i­can Acad­e­my of Neu­rol­o­gy’s an­nu­al meet­ing to dis­cuss the lat­est ad­vance­ments and clin­i­cal tri­ ...